---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-092465"
form_type: "8-K"
ticker: "KURA"
cik: "0001422143"
company_name: "Kura Oncology, Inc."
filed_at: "2026-03-05T23:59:59+00:00"
generated_at: "2026-05-15T19:29:46.172196+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Kura Oncology Q4 2025 net loss $81M; KOMZIFTI launch revenue $2.1M in first 5 weeks

## Summary
- Net loss of $81.0M in Q4 2025 vs $19.2M a year ago; full-year net loss $219.4M.
- Net product revenue $2.1M from KOMZIFTI in first five weeks of commercial sales post Nov 13 FDA approval.
- Collaboration revenue $15.2M (Kyowa Kirin milestones); R&D $64.4M, SG&A $39.1M.
- Cash and investments $667.2M; plus $180M in anticipated Kyowa Kirin payments expected to fund through KOMET-017 Phase 3 topline (2028).
- 2026 milestones include updated KOMET-007 data, KOMET-015 enrollment in GIST, and darlifarnib data in KRAS G12C tumors.

## SEC filing metadata
- accession: 0001193125-26-092465
- form_type: 8-K
- ticker: KURA
- cik: 0001422143
- company_name: Kura Oncology, Inc.
- filed_at: 2026-03-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422143/000119312526092465/0001193125-26-092465-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422143/000119312526092465/kura-20260305.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-092465
- JSON: https://secwatch.observer/filing/0001193125-26-092465.json
- Plain text: https://secwatch.observer/filing/0001193125-26-092465.txt

## Key facts
- Earnings Releases
  Kura Oncology, Inc. reported the fourth quarter ended December 31, 2025 results: revenue Net product revenue: $2.1 million; Collaboration revenue: $15.2 million.
  - Period: the fourth quarter ended December 31, 2025
  - Revenue: Net product revenue: $2.1 million; Collaboration revenue: $15.2 million
  - Result: reported results
  source text: Fourth Quarter 2025 Financial Results • Net product revenue: $2.1 million (first five weeks of commercial sales following November 13 approval of KOMZIFTI). • Collaboration revenue: $15.2 million, compared to $53.9 million for Q4
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422143/000119312526092465/0001193125-26-092465-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.